Details of the Drug Combinations

General Information of This Drug (ID: DM04LR2)

• Drug Name: Floxuridine (DM04LR2)
• Synonyms: floxuridine; 50-91-9; 2'-Deoxy-5-fluorouridine; 5-Fluorodeoxyuridine; Fluorodeoxyuridine; Floxuridin; FUDR; Fluoruridine deoxyribose; Deoxyfluorouridine; 5-Fluoro-2'-deoxyuridine; FdUrd; Floxuridinum; Floxiridina; 5FdU; 5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione; 5-Fluoro-2-desoxyuridine; 5 Fluorodeoxyuridine; Floxuridinum [INN-Latin]; FDUR; Floxiridina [INN-Spanish]; beta-5-Fluoro-2'-deoxyuridine; 5-Fluoro-2-deoxyuridine; 5-FdUrd; 5-Fluorouracil deoxyriboside; Sterile fudr (TN); Floxuridine/5-fluorouracil

Indication

Colorectal cancer; ICD 11: 2B91.Z; Status: Approved [1]; Liver cancer; ICD 11: 2C12; Status: Approved [2]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Approved [3]; Colon cancer; ICD 11: 2B90.Z; Status: Investigative [2]; Gastric cancer; ICD 11: 2B72; Status: Investigative [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Floxuridine + Idarubicin	DC92FFA	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]

11 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Floxuridine + Dexamethasone	DC06PQL	Dexamethasone	Liver Cancer	[5]
Floxuridine + Irinotecan	DCHW99N	Irinotecan	Colorectal Cancer	[6]
Floxuridine + Dexamethasone	DC87X4Q	Dexamethasone	Intrahepatic Cholangiocarcinoma	[7]
Floxuridine + Dexamethasone	DCW0VKM	Dexamethasone	Nasopharyngeal Carcinoma	[8]
Floxuridine + Docetaxel	DC69W1Q	Docetaxel	Gastric Cancer	[9]
Floxuridine + Dexamethasone	DCBDLWC	Dexamethasone	Intrahepatic Cholangiocarcinoma	[10]
Floxuridine + Docetaxel	DCJV4WA	Docetaxel	Esophageal Cancer	[11]
Floxuridine + Dexamethasone	DCNY0P5	Dexamethasone	Colorectal Cancer	[12]
Floxuridine + Dexamethasone	DCRMCAS	Dexamethasone	Adenocarcinoma of the Colon	[13]
Floxuridine + Irinotecan	DCG3WT9	Irinotecan	Colo-rectal Cancer	[14]
Floxuridine + Oxaliplatin	DCZZPAN	Oxaliplatin	Colorectal Cancer	[15]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] Floxuridine FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4801).
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] ClinicalTrials.gov (NCT00410956) Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
• [6] ClinicalTrials.gov (NCT00063960) Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer
• [7] ClinicalTrials.gov (NCT01938729) Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
• [8] ClinicalTrials.gov (NCT03876574) Hepatic Artery Infusion Pump for NPC Liver Metastases
• [9] ClinicalTrials.gov (NCT00448682) Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
• [10] ClinicalTrials.gov (NCT01862315) Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
• [11] ClinicalTrials.gov (NCT00448760) Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
• [12] ClinicalTrials.gov (NCT00492999) Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
• [13] ClinicalTrials.gov (NCT00026234) Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
• [14] ClinicalTrials.gov (NCT03493061) A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
• [15] ClinicalTrials.gov (NCT00268463) Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer